How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Stem Cell Drugs Market
- By Stem Cell Type: Embryonic Stem Cells (ESCs), Adult Stem Cells (ASCs), Induced Pluripotent Stem Cells (iPSCs), Mesenchymal Stem Cells (MSCs), Hematopoietic Stem Cells (HSCs)
- By Therapeutic Application: Orthopedic Disorders, Cardiovascular Diseases, Neurological Disorders, Autoimmune Diseases, Ophthalmic Disorders, Wound Healing and Tissue Regeneration
- By Product Type: Stem Cell Therapeutics, Stem Cell-Derived Biologics, Stem Cell-Based Gene Therapy, Stem Cell Culture Media and Reagents, Stem Cell Delivery Systems
- By End User: Hospitals and Clinics, Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Academic and Government Research Laboratories
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Embryonic Stem Cells (ESCs) leads By Stem Cell Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.171 →
- 11 Company Profiles 17 players: SWOT & benchmarking p.179 →
Full report · locked preview
Everything inside the Stem Cell Drugs Market report
A complete, evidence-based study - 11 chapters and 121 sections covering market size, segmentation across 4 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Stem Cell Type 5
Therapeutic Application 6
Product Type 5
End User 5
Companies profiled
Mesoblast Limited
Osiris Therapeutics (a subsidiary of Smith & Nephew)
Athersys Inc.
Fate Therapeutics Inc.
Pluristem Therapeutics Inc.
Cytori Therapeutics Inc.
Vericel Corporation
TiGenix NV (now part of Takeda Pharmaceutical Company)
Gamida Cell Ltd.
Anterogen Co. Ltd.
Medipost Co. Ltd.
Celltex Therapeutics Corporation
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Mesoblast Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Osiris Therapeutics (a subsidiary of Smith & Nephew)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Athersys Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Fate Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Pluristem Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Cytori Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Vericel Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →TiGenix NV (now part of Takeda Pharmaceutical Company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Gamida Cell Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Anterogen Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Medipost Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Celltex Therapeutics Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →BrainStorm Cell Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →ReNeuron Group plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →BioTime
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc. (now Lineage Cell Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc.)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,611M by 2033 · 11.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Embryonic Stem Cells (ESCs)49.4
- Adult Stem Cells (ASCs)16.2
- Induced Pluripotent Stem Cells (iPSCs)10.7
- Mesenchymal Stem Cells (MSCs)8.2
- Hematopoietic Stem Cells (HSCs)15.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$913.7M → $2,137M · 11.2%
Europe$636.8M → $1,685M · 12.9%
Asia Pacific$581.4M → $1,327M · 10.9%
Latin America$359.9M → $894.7M · 12.1%
Middle East and Africa$276.9M → $688.7M · 12.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.442026
11.462027
11.482028
11.492029
11.492030
11.502031
11.522032
11.532033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Mesoblast Limited26.0
- Osiris Therapeutics (a subsidiary of Smith & Nephew)18.3
- Athersys Inc.7.4
- Fate Therapeutics Inc.4.7
- Pluristem Therapeutics Inc.10.1
- Cytori Therapeutics Inc.5.6
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Stem Cell Type27.5%
Therapeutic Application21.4%
Product Type38.4%
End User12.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.7
- Europe25.0
- Asia Pacific19.7
- Latin America13.3
- Middle East and Africa10.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Mesoblast Limited | 79 | 97 | 86 | 78 | 99 | 92 | 89 |
| Osiris Therapeutics (a subsidiary of Smith & Nephew) | 82 | 73 | 83 | 79 | 68 | 87 | 79 |
| Athersys Inc. | 62 | 80 | 71 | 66 | 77 | 68 | 71 |
| Fate Therapeutics Inc. | 57 | 60 | 77 | 73 | 62 | 80 | 68 |
| Pluristem Therapeutics Inc. | 57 | 53 | 71 | 71 | 61 | 53 | 61 |
| Cytori Therapeutics Inc. | 67 | 58 | 51 | 47 | 64 | 55 | 57 |
| Vericel Corporation | 60 | 52 | 47 | 49 | 64 | 62 | 56 |
| TiGenix NV (now part of Takeda Pharmaceutical Company) | 40 | 60 | 54 | 44 | 36 | 56 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Mesoblast Limited
- Osiris Therapeutics (a subsidiary of Smith & Nephew)
- Athersys Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Mesoblast Limited | ◐ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Osiris Therapeutics (a subsidiary of Smith & Nephew) | ◐ | − | ✓ | ◐ | ◐ | ✓ |
| Athersys Inc. | ◐ | ◐ | − | ◐ | ◐ | ◐ |
| Fate Therapeutics Inc. | − | ◐ | ◐ | − | ◐ | ✓ |
| Pluristem Therapeutics Inc. | − | − | ◐ | ◐ | − | ◐ |
| Cytori Therapeutics Inc. | ◐ | − | − | ◐ | ◐ | − |
| Vericel Corporation | − | ◐ | − | ◐ | ◐ | − |
| TiGenix NV (now part of Takeda Pharmaceutical Company) | ◐ | ◐ | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Mesoblast Limited89
2Osiris Therapeutics (a subsidiary of Smith & Nephew)79
3Athersys Inc.71
4Fate Therapeutics Inc.68
5Pluristem Therapeutics Inc.61
6Cytori Therapeutics Inc.57
7Vericel Corporation56
8TiGenix NV (now part of Takeda Pharmaceutical Company)48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Mesoblast LimitedOsiris Therapeutics (a subsidiary of Smith & Nephew)
Challenger2
Strong scale, closing on the leaders.
Athersys Inc.Fate Therapeutics Inc.
Contender2
Focused players with pockets of strength.
Pluristem Therapeutics Inc.Cytori Therapeutics Inc.
Niche2
Specialists in a single segment or region.
Vericel CorporationTiGenix NV (now part of Takeda Pharmaceutical Company)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Stem Cell Type in North America, then scale across Stem Cell Drugs Market — a $161M beachhead inside a $2.33B market.
Beachhead (SOM)$161Mobtainable near-term
Serviceable (SAM)$931Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Embryonic Stem Cells (ESCs)
Best fit — highest urgency & budget in Stem Cell Type.
Economic buyer78 fit
Adult Stem Cells (ASCs)
Strong fit — clear ROI and a fast path to value.
End user65 fit
Induced Pluripotent Stem Cells (iPSCs)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Stem Cell Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapeutic Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Product Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel26%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Stem Cell Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Stem Cell Drugs Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified23%
Evaluation13%
Closed-won5%
$15.2KCAC
$58KLTV
3.8:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Stem Cell Drugs Market is a durable-growth opportunity — $9.11B by 2033, compounding at 7.3%.
TAM · 2025$5.18Btoday
TAM · 2033$9.11Bforecast
CAGR7.3%2027–2033
Cumulative$62.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.11BTotal addressable market
SAM$3.43BServiceable available market
SOM$629MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.3% CAGR
Demand compounds through 2033, outpacing GDP across Stem Cell Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Stem Cell Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.11BLarge & growingTAM by 2033 at 7.3% CAGR
$3.43BServiceable nowreachable with today’s model
$629MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.10BBear4.7% CAGR
$9.11BBase7.3% CAGR
$11.7BBull9.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapeutic Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Stem Cell Drugs Market — a $9.02B market by 2033. Plan: grow share from 9.0% to 18.0%.
Market size · 2033$9.02Btotal addressable
Market CAGR6.7%2027–2033
Target share18.0%from 9.0% today
Revenue ambition$1.62Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.0% | 18.0% | On track |
| Revenue | $762M | $1.62B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 34.2% | 43.9% | At risk |
| Customer retention | 84.5% | 94.2% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Stem Cell Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapeutic Application capability
A defensible second engine — invest in Therapeutic Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Stem Cell Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapeutic Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $225M capacity & capability investment
- Greenlight bolt-on M&A in Therapeutic Application
- Authorise North America expansion plan
- Fund R&D program for Stem Cell Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Stem Cell Drugs Market conversation — a $3.19B market you can size, segment and defend in minutes.
Market size · 2033$3.19Btotal opportunity
Growth4.3%CAGR to 2033
Addressable buyers1,002+accounts in scope
Typical ROI6.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Stem Cell Type
Goal Grow share in Stem Cell Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.6×return on cost, year one
< 3 mopayback period
$87K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Mesoblast LimitedOsiris Therapeutics (a subsidiary of Smith & Nephew)Athersys Inc.Fate Therapeutics Inc.Pluristem Therapeutics Inc.Cytori Therapeutics Inc.Vericel CorporationTiGenix NV (now part of Takeda Pharmaceutical Company)+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Stem Cell Drugs Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Stem Cell Drugs Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Stem Cell Culture Medium Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportStem Cell Culture Media Market
Market size, share, segmentation and regional forecast.
$987M market · 2025 base year
View reportStem Cell Cryopreservation Equipment Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportStem Cell Concentration System Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportStem Cell Complete Media Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportStem Cell Characterization Kits Market
Market size, share, segmentation and regional forecast.
$713M market · 2025 base year
View reportStem Cell Characterization and Analysis Tool Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportStelara Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportStein Leventhal Syndrome Drugs Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportSteerable Sheath Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportSteerable Microcatheters Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportSteerable Introducer Sheath Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.